Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Dimotane Co oral solution paediatric sugar free
0309020U0BBABAB
|
Dimotane (Expectorant/Demulcents) | Brompheniramine maleate combinations | Respiratory System | No data available |
|
Dimotane Co oral solution sugar free
0309020U0BBAAAA
|
Dimotane (Expectorant/Demulcents) | Brompheniramine maleate combinations | Respiratory System | No data available |
|
Dimotane Expectorant oral solution
0309020U0BBADAC
|
Dimotane (Expectorant/Demulcents) | Brompheniramine maleate combinations | Respiratory System | No data available |
|
Dimotane Plus oral solution
0310000N0BFABAJ
|
Dimotane Plus | Pseudoephedrine hydrochloride | Respiratory System | No data available |
|
Dimotane Plus Paediatric elixir
0310000N0BFAAAI
|
Dimotane Plus | Pseudoephedrine hydrochloride | Respiratory System | No data available |
|
Dinneford's Teejel gel
1203010K0BCAAAB
|
Teejel | Choline salicylate | Ear, Nose and Oropharynx | No data available |
|
Dinoprostone 10mg vaginal device
0701010I0AAAHAH
|
Dinoprostone | Dinoprostone | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Dinoprostone 1mg/2.5ml vaginal gel
0701010I0AAAFAF
|
Dinoprostone | Dinoprostone | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Dinoprostone 2mg/2.5ml vaginal gel
0701010I0AAAGAG
|
Dinoprostone | Dinoprostone | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Dinoprostone 3mg pessaries
0701010I0AAAAAA
|
Dinoprostone | Dinoprostone | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Dinoprostone 5mg/0.5ml solution for infusion ampoules
0701010I0AAADAD
|
Dinoprostone | Dinoprostone | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Dinoprostone 750micrograms/0.75ml inf ampoules
0701010I0AAAEAE
|
Dinoprostone | Dinoprostone | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Diocalm Complete pack
0104020L0BNAAAM
|
Diocalm Complete | Loperamide hydrochloride | Gastro-Intestinal System | No data available |
|
Diocalm Dual Action chewable tablets
0104020N0BBAAAC
|
Diocalm (Diarrhoea) | Opium and morphine | Gastro-Intestinal System | No data available |
|
Diocalm Ultra 2mg capsules
0104020L0BEAAAA
|
Diocalm Ultra (Acute Diarrhoea) | Loperamide hydrochloride | Gastro-Intestinal System | No data available |
|
Diocaps 2mg capsules
0104020L0BFAAAA
|
Diocaps | Loperamide hydrochloride | Gastro-Intestinal System | No data available |
|
Dioraleze 2mg capsules
0104020L0BUAAAA
|
Dioraleze | Loperamide hydrochloride | Gastro-Intestinal System | No data available |
|
Dioralyte effervescent tablets blackcurrant
0902012H0BBAIAA
|
Dioralyte | Oral rehydration salts | Nutrition and Blood | No data available |
|
Dioralyte effervescent tablets citrus
0902012H0BBAHAA
|
Dioralyte | Oral rehydration salts | Nutrition and Blood | No data available |
|
Dioralyte Relief oral powder sachets apricot
0902012H0BBAJAJ
|
Dioralyte | Oral rehydration salts | Nutrition and Blood | No data available |
|
Diosmin 450mg / Hesperidin 50mg tablets
0206040ATAAAAAA
|
Diosmin/hesperidin | Diosmin/hesperidin | Cardiovascular System | No data available |
|
Diovan 160mg capsules
0205052V0BBACAC
|
Diovan | Valsartan | Cardiovascular System | No data available |
|
Diovan 320mg tablets
0205052V0BBAEAF
|
Diovan | Valsartan | Cardiovascular System | No data available |
|
Diovan 40mg capsules
0205052V0BBAAAA
|
Diovan | Valsartan | Cardiovascular System | No data available |
|
Diovan 40mg tablets
0205052V0BBADAD
|
Diovan | Valsartan | Cardiovascular System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.